Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Prognostic value of HER2-low status in breast cancer: A systematic review and meta-analysis

Dr Chiara Molinelli - Università degli Studi di Genova, Genoa, Italy
Prognostic value of HER2-low status in breast cancer: A systematic review and meta-analysis ( Dr Chiara Molinelli - Università degli Studi di Genova, Genoa, Italy )
6 Jun 2023

Extended lymph node removal does not benefit patients with clinically localised muscle-invasive bladder cancer

Dr Seth Lerner - Baylor College of Medicine, Houston, USA
Extended lymph node removal does not benefit patients with clinically localised muscle-invasive bladder cancer ( Dr Seth Lerner - Baylor College of Medicine, Houston, USA )
6 Jun 2023

Dostarlimab chemo combination for primary advanced or recurrent endometrial cancer

Prof Matthew Powell - Washington University School of Medicine, Missouri, USA
Dostarlimab chemo combination for primary advanced or recurrent endometrial cancer ( Prof Matthew Powell - Washington University School of Medicine, Missouri, USA )
6 Jun 2023

2L triple metronomic chemo shows more efficacy in comparison to systemic therapy for head and neck cancer

Dr Rushabh Kiran Kothari (PI, CRSF group) - Narayana Multispeciality Hospital, Ahmedabad, India
2L triple metronomic chemo shows more efficacy in comparison to systemic therapy for head and neck cancer ( Dr Rushabh Kiran Kothari (PI, CRSF group) - Narayana Multispeciality Hospital, Ahmedabad, India )
5 Jun 2023

ASCO 2023: Breast cancer research highlights

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
ASCO 2023: Breast cancer research highlights ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )
5 Jun 2023

Ciltacabtagene autoleucel greatly reduces risk of disease progression in lenalidomide-refractory MM

Dr Binod Dhakal - Medical College of Wisconsin, Milwaukee, USA
Ciltacabtagene autoleucel greatly reduces risk of disease progression in lenalidomide-refractory MM ( Dr Binod Dhakal - Medical College of Wisconsin, Milwaukee, USA )
5 Jun 2023

mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit and increases toxicity

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit and increases toxicity ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )
5 Jun 2023

Effectiveness of a cardiovascular health EHR application for cancer survivors in community oncology practice

Prof Kathryn Weaver - Wake Forest School of Medicine, Winston-Salem, USA
Effectiveness of a cardiovascular health EHR application for cancer survivors in community oncology practice ( Prof Kathryn Weaver - Wake Forest School of Medicine, Winston-Salem, USA )
5 Jun 2023

ASCO 2023: Head and neck highlights

Dr Glenn Hanna - Dana-Farber Cancer Institute, Boston, USA
ASCO 2023: Head and neck highlights ( Dr Glenn Hanna - Dana-Farber Cancer Institute, Boston, USA )
5 Jun 2023

Baseline liquid biopsy results in treatment efficacy of FOLFIRI/cetuximab in patients with tissue RAS-WT mCRC

Prof Sebastian Stintzing - Universitätsmedizin Berlin, Berlin, Germany
Baseline liquid biopsy results in treatment efficacy of FOLFIRI/cetuximab in patients with tissue RAS-WT mCRC ( Prof Sebastian Stintzing - Universitätsmedizin Berlin, Berlin, Germany )
4 Jun 2023

Real-world behavioural restrictional practices of cancer patients

Dr Eliya Shahar - Tel Aviv University, Tel Aviv, Israel
Real-world behavioural restrictional practices of cancer patients ( Dr Eliya Shahar - Tel Aviv University, Tel Aviv, Israel )
4 Jun 2023

Elranatamab shows efficacy in RRMM with prior BCMA-directed treatment

Prof Ajay Nooka - Winship Cancer Center of Emory University, Atlanta, USA
Elranatamab shows efficacy in RRMM with prior BCMA-directed treatment ( Prof Ajay Nooka - Winship Cancer Center of Emory University, Atlanta, USA )
4 Jun 2023